Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Accured Expenses: 2023-2024

Historic Change in Accured Expenses for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $35.9 million.

  • Inhibrx Biosciences' Change in Accured Expenses fell 125.12% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 94.18%. This contributed to the annual value of $35.9 million for FY2024, which is 37.64% up from last year.
  • Inhibrx Biosciences' Change in Accured Expenses amounted to $35.9 million in FY2024, which was up 37.64% from $26.1 million recorded in FY2023.
  • Inhibrx Biosciences' 5-year Change in Accured Expenses high stood at $35.9 million for FY2024, and its period low was $26.1 million during FY2023.
  • Its 2-year average for Change in Accured Expenses is $31.0 million, with a median of $31.0 million in 2023.
  • Data for Inhibrx Biosciences' Change in Accured Expenses shows a peak YoY surged of 37.64% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Change in Accured Expenses (Yearly) stood at $26.1 million in 2023, then soared by 37.64% to $35.9 million in 2024.